Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR.

Mol Pharmacol. 2019 Jun;95(6):638-651. doi: 10.1124/mol.118.115196. Epub 2019 Apr 12.

PMID:
30979813
2.

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations.

Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC.

Front Oncol. 2018 Oct 12;8:425. doi: 10.3389/fonc.2018.00425. eCollection 2018.

3.

Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control.

Kakadia PM, Van de Water N, Browett PJ, Bohlander SK.

Sci Rep. 2018 Sep 13;8(1):13751. doi: 10.1038/s41598-018-31503-5.

4.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW.

JCI Insight. 2018 Aug 23;3(16). pii: 122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23.

5.

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.

Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. Epub 2017 May 19.

PMID:
28420034
6.

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.

Kakadia PM, Schmidmaier R, Völkl A, Schneider I, Huk N, Schneider S, Panzner G, Neidel U, Fritz B, Spiekermann K, Bohlander SK.

Leuk Res Rep. 2016 Oct 14;6:50-54. eCollection 2016.

7.

DNA Repair and Chromosomal Translocations.

Bohlander SK, Kakadia PM.

Recent Results Cancer Res. 2015;200:1-37. doi: 10.1007/978-3-319-20291-4_1. Review.

PMID:
26376870
8.

Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta.

Garbes L, Kim K, Rieß A, Hoyer-Kuhn H, Beleggia F, Bevot A, Kim MJ, Huh YH, Kweon HS, Savarirayan R, Amor D, Kakadia PM, Lindig T, Kagan KO, Becker J, Boyadjiev SA, Wollnik B, Semler O, Bohlander SK, Kim J, Netzer C.

Am J Hum Genet. 2015 Mar 5;96(3):432-9. doi: 10.1016/j.ajhg.2015.01.002. Epub 2015 Feb 12.

9.

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Blood. 2014 Aug 21;124(8):1304-11. doi: 10.1182/blood-2013-12-540716. Epub 2014 Jun 12.

10.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.

PMID:
24912430
11.

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E.

J Clin Oncol. 2014 May 20;32(15):1586-94. doi: 10.1200/JCO.2013.52.3480. Epub 2014 Apr 7.

12.

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.

Opatz S, Polzer H, Herold T, Konstandin NP, Ksienzyk B, Zellmeier E, Vosberg S, Graf A, Krebs S, Blum H, Hopfner KP, Kakadia PM, Schneider S, Dufour A, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA.

Blood. 2013 Sep 5;122(10):1761-9. doi: 10.1182/blood-2013-01-476473. Epub 2013 Jul 22.

13.

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, Benthaus T, Kakadia PM, Spiekermann K, Hiddemann W, Braess J, Truong S, Patten N, Wu L, Lohmann S, Dornan D, GuhaThakurta D, Yeh RF, Salogub G, Solal-Celigny P, Dmoszynska A, Robak T, Montillo M, Catalano J, Geisler CH, Weisser M, Bohlander SK.

Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.

14.

High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.

Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK.

Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.

PMID:
23189934
15.

FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia.

Pašaliç Z, Greif PA, Jurinoviç V, Mulaw M, Kakadia PM, Tizazu B, Fröhlich-Archangelo L, Krause A, Bohlander SK.

Blood Cancer J. 2011 Nov;1(11):e42. doi: 10.1038/bcj.2011.40. Epub 2011 Nov 11.

16.

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.

Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11.

17.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Blood. 2012 Jul 12;120(2):395-403. doi: 10.1182/blood-2012-01-403220. Epub 2012 May 30.

18.

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Büchner T, Wörmann BJ, Hiddemann W, Spiekermann K.

Blood. 2012 May 10;119(19):4383-6. doi: 10.1182/blood-2010-12-327072. Epub 2012 Feb 28.

19.

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24.

PMID:
22362118
20.

Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).

Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K.

Ann Hematol. 2012 Jan;91(1):9-18. doi: 10.1007/s00277-011-1280-6. Epub 2011 Jul 9.

PMID:
21744003
21.

A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL).

Kakadia PM, Tizazu B, Mellert G, Harbott J, Röttgers S, Quentmeier H, Spiekermann K, Bohlander SK.

Leukemia. 2011 Oct;25(10):1645-9. doi: 10.1038/leu.2011.129. Epub 2011 May 31. No abstract available.

PMID:
21625237
22.

Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia.

Konstandin N, Bultmann S, Szwagierczak A, Dufour A, Ksienzyk B, Schneider F, Herold T, Mulaw M, Kakadia PM, Schneider S, Spiekermann K, Leonhardt H, Bohlander SK.

Leukemia. 2011 Oct;25(10):1649-52. doi: 10.1038/leu.2011.134. Epub 2011 May 31. No abstract available.

PMID:
21625234
23.

An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.

Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, Mulaw M, Thoene S, Dufour A, Pasalic Z, Schmidberger M, Schmidt M, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK.

Leukemia. 2011 Oct;25(10):1639-45. doi: 10.1038/leu.2011.125. Epub 2011 May 31. No abstract available.

PMID:
21625232
24.

Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.

Herold T, Jurinovic V, Mulaw M, Seiler T, Dufour A, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK.

Genes Chromosomes Cancer. 2011 Jul;50(7):546-58. doi: 10.1002/gcc.20879. Epub 2011 Apr 15.

PMID:
21500311
25.

Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias.

Lin YH, Kakadia PM, Chen Y, Li YQ, Deshpande AJ, Buske C, Zhang KL, Zhang Y, Xu GL, Bohlander SK.

Blood. 2009 Jul 16;114(3):651-8. doi: 10.1182/blood-2009-03-209395. Epub 2009 May 14.

26.

Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.

Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM, Hiddemann W, Bohlander SK, Feuring-Buske M, Braess J, Spiekermann K, Dufour A.

Br J Haematol. 2008 Oct;143(2):230-9. doi: 10.1111/j.1365-2141.2008.07328.x. Epub 2008 Aug 24.

PMID:
18752591
27.

Characterization of a familial small supernumerary marker chromosome in a patient with adult-onset tongue cancer.

Bakshi SR, Dave BJ, Sanger W, Brahmbhatt MM, Trivedi PJ, Kakadia PM, Patel SJ.

Cytogenet Genome Res. 2008;121(1):14-7. doi: 10.1159/000124376. Epub 2008 May 7.

PMID:
18544921
28.

Aplastic anemia and Klinefelter syndrome.

Bakshi SR, Trivedi PJ, Brahmbhatt MM, Rawal SM, Kakadia PM, Bhatt SS, Shukla SN.

Cancer Genet Cytogenet. 2004 Oct 1;154(1):91-2. No abstract available.

PMID:
15381382

Supplemental Content

Loading ...
Support Center